Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Return on Invested Capital (2019 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Return on Invested Capital for 5 consecutive years, with 0.13% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital fell 2.0% year-over-year to 0.13%, compared with a TTM value of 0.13% through Dec 2025, down 2.0%, and an annual FY2025 reading of 0.14%, down 2.0% over the prior year.
  • Return on Invested Capital was 0.13% for Q4 2025 at Neurocrine Biosciences, up from 0.13% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.16% in Q1 2024 and bottomed at 0.04% in Q1 2023.
  • Average Return on Invested Capital over 4 years is 0.12%, with a median of 0.13% recorded in 2025.
  • The sharpest move saw Return on Invested Capital dropped -11bps in 2021, then rose 13bps in 2024.
  • Year by year, Return on Invested Capital stood at 0.09% in 2021, then fell by -8bps to 0.08% in 2023, then soared by 85bps to 0.15% in 2024, then fell by -11bps to 0.13% in 2025.
  • Business Quant data shows Return on Invested Capital for NBIX at 0.13% in Q4 2025, 0.13% in Q3 2025, and 0.13% in Q2 2025.